Table of Contents
When Onyx caught up with CEO Fabian Gerlinghaus at JPM 2026, we'd just heard groundbreaking news.
Cabaletta Bio’s investigational CAR T cell therapy 'rese-cel' had received FDA clearance of an IND Amendment to use Cellares’ Cell Shuttle platform for manufacturing.
The theory - 10x throughput, 50% lower prices per batch, 75% lower process failure rates - was about to translate into reality. Life-saving, affordable treatments for patients.
Many would take a day off.
But instead, Cellares announced a $257 Million Series D raise, led by BlackRock and Eclipse.
They also announced a collaboration with Stanford University to automate manufacturing and release testing for gene-edited hematopoietic stem cell therapies.
It was our pleasure to interview the CEO of one of the most exciting and fast-moving companies in the industry.
A special thanks to our Onyx Live sponsors:
HUMPHREYS LAW - a focused, full-service law firm advising clients in the technology and media sectors. https://humphreys.law/
Panacea - AI-powered FDA consultants. File your IND in half the time. https://withpanacea.com/
Yours sincerely,
Dr. Adil Ali
Comments